Association of activated vitamin D treatment and mortality in chronic kidney disease

Csaba Kovesdy, Shahram Ahmadzadeh, John E. Anderson, Kamyar Kalantar-Zadeh

Research output: Contribution to journalArticle

241 Citations (Scopus)

Abstract

Background: Treatment of secondary hyperparathyroidism (SHPT) with activated vitamin D analogues is associated with better survival in patients receiving dialysis. It is unclear whether such a benefit is present in patients with predialysis chronic kidney disease (CKD). Methods: We examined the association of oral calcitriol treatment with mortality and the incidence of dialysis in 520 male US veterans (mean [SD] age, 69.8 [10.3] years; 23.5% black) with CKD stages 3 to 5 and not yet receiving dialysis (mean [SD] estimated glomerular filtration rate, 30.8 [11.3]). Associations were examined by the Kaplan-Meier method and in Poisson regression models with adjustment for age, race, comorbidities, smoking, blood pressure, body mass index, use of phosphate binders, estimated glomerular filtration rate, proteinuria, white blood cell count, percentage of lymphocytes, and levels of parathyroid hormone, calcium, phosphorus, albumin, bicarbonate, and hemoglobin. Results: Two hundred fifty-eight of 520 subjects received treatment with calcitriol, 0.25 to 0.5 μg/d, for a median duration of 2.1 years (range, 0.06-6.0 years). The incidence rate ratios for mortality and combined death and dialysis initiation were significantly lower in treated vs untreated patients (P<.001 for both in the fully adjusted models). Treatment with calcitriol was associated with a trend toward a lower incidence of dialysis. These results were consistent across different subgroups. Conclusions: Treatment with the activated vitamin D analogue calcitriol appears to be associated with significantly greater survival in patients with CKD not yet receiving dialysis. Randomized clinical trials are required to verify the causality of these associations and to examine whether similar associations are seen with different activated vitamin D analogues.

Original languageEnglish (US)
Pages (from-to)397-403
Number of pages7
JournalArchives of Internal Medicine
Volume168
Issue number4
DOIs
StatePublished - Feb 25 2008

Fingerprint

Chronic Renal Insufficiency
Vitamin D
Dialysis
Calcitriol
Mortality
Glomerular Filtration Rate
Incidence
Therapeutics
Secondary Hyperparathyroidism
Survival
Veterans
Bicarbonates
Parathyroid Hormone
Leukocyte Count
Proteinuria
Causality
Phosphorus
Comorbidity
Albumins
Hemoglobins

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Association of activated vitamin D treatment and mortality in chronic kidney disease. / Kovesdy, Csaba; Ahmadzadeh, Shahram; Anderson, John E.; Kalantar-Zadeh, Kamyar.

In: Archives of Internal Medicine, Vol. 168, No. 4, 25.02.2008, p. 397-403.

Research output: Contribution to journalArticle

Kovesdy, Csaba ; Ahmadzadeh, Shahram ; Anderson, John E. ; Kalantar-Zadeh, Kamyar. / Association of activated vitamin D treatment and mortality in chronic kidney disease. In: Archives of Internal Medicine. 2008 ; Vol. 168, No. 4. pp. 397-403.
@article{f5b5b4d951834e6cb0a434c059d865ea,
title = "Association of activated vitamin D treatment and mortality in chronic kidney disease",
abstract = "Background: Treatment of secondary hyperparathyroidism (SHPT) with activated vitamin D analogues is associated with better survival in patients receiving dialysis. It is unclear whether such a benefit is present in patients with predialysis chronic kidney disease (CKD). Methods: We examined the association of oral calcitriol treatment with mortality and the incidence of dialysis in 520 male US veterans (mean [SD] age, 69.8 [10.3] years; 23.5{\%} black) with CKD stages 3 to 5 and not yet receiving dialysis (mean [SD] estimated glomerular filtration rate, 30.8 [11.3]). Associations were examined by the Kaplan-Meier method and in Poisson regression models with adjustment for age, race, comorbidities, smoking, blood pressure, body mass index, use of phosphate binders, estimated glomerular filtration rate, proteinuria, white blood cell count, percentage of lymphocytes, and levels of parathyroid hormone, calcium, phosphorus, albumin, bicarbonate, and hemoglobin. Results: Two hundred fifty-eight of 520 subjects received treatment with calcitriol, 0.25 to 0.5 μg/d, for a median duration of 2.1 years (range, 0.06-6.0 years). The incidence rate ratios for mortality and combined death and dialysis initiation were significantly lower in treated vs untreated patients (P<.001 for both in the fully adjusted models). Treatment with calcitriol was associated with a trend toward a lower incidence of dialysis. These results were consistent across different subgroups. Conclusions: Treatment with the activated vitamin D analogue calcitriol appears to be associated with significantly greater survival in patients with CKD not yet receiving dialysis. Randomized clinical trials are required to verify the causality of these associations and to examine whether similar associations are seen with different activated vitamin D analogues.",
author = "Csaba Kovesdy and Shahram Ahmadzadeh and Anderson, {John E.} and Kamyar Kalantar-Zadeh",
year = "2008",
month = "2",
day = "25",
doi = "10.1001/archinternmed.2007.110",
language = "English (US)",
volume = "168",
pages = "397--403",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Association of activated vitamin D treatment and mortality in chronic kidney disease

AU - Kovesdy, Csaba

AU - Ahmadzadeh, Shahram

AU - Anderson, John E.

AU - Kalantar-Zadeh, Kamyar

PY - 2008/2/25

Y1 - 2008/2/25

N2 - Background: Treatment of secondary hyperparathyroidism (SHPT) with activated vitamin D analogues is associated with better survival in patients receiving dialysis. It is unclear whether such a benefit is present in patients with predialysis chronic kidney disease (CKD). Methods: We examined the association of oral calcitriol treatment with mortality and the incidence of dialysis in 520 male US veterans (mean [SD] age, 69.8 [10.3] years; 23.5% black) with CKD stages 3 to 5 and not yet receiving dialysis (mean [SD] estimated glomerular filtration rate, 30.8 [11.3]). Associations were examined by the Kaplan-Meier method and in Poisson regression models with adjustment for age, race, comorbidities, smoking, blood pressure, body mass index, use of phosphate binders, estimated glomerular filtration rate, proteinuria, white blood cell count, percentage of lymphocytes, and levels of parathyroid hormone, calcium, phosphorus, albumin, bicarbonate, and hemoglobin. Results: Two hundred fifty-eight of 520 subjects received treatment with calcitriol, 0.25 to 0.5 μg/d, for a median duration of 2.1 years (range, 0.06-6.0 years). The incidence rate ratios for mortality and combined death and dialysis initiation were significantly lower in treated vs untreated patients (P<.001 for both in the fully adjusted models). Treatment with calcitriol was associated with a trend toward a lower incidence of dialysis. These results were consistent across different subgroups. Conclusions: Treatment with the activated vitamin D analogue calcitriol appears to be associated with significantly greater survival in patients with CKD not yet receiving dialysis. Randomized clinical trials are required to verify the causality of these associations and to examine whether similar associations are seen with different activated vitamin D analogues.

AB - Background: Treatment of secondary hyperparathyroidism (SHPT) with activated vitamin D analogues is associated with better survival in patients receiving dialysis. It is unclear whether such a benefit is present in patients with predialysis chronic kidney disease (CKD). Methods: We examined the association of oral calcitriol treatment with mortality and the incidence of dialysis in 520 male US veterans (mean [SD] age, 69.8 [10.3] years; 23.5% black) with CKD stages 3 to 5 and not yet receiving dialysis (mean [SD] estimated glomerular filtration rate, 30.8 [11.3]). Associations were examined by the Kaplan-Meier method and in Poisson regression models with adjustment for age, race, comorbidities, smoking, blood pressure, body mass index, use of phosphate binders, estimated glomerular filtration rate, proteinuria, white blood cell count, percentage of lymphocytes, and levels of parathyroid hormone, calcium, phosphorus, albumin, bicarbonate, and hemoglobin. Results: Two hundred fifty-eight of 520 subjects received treatment with calcitriol, 0.25 to 0.5 μg/d, for a median duration of 2.1 years (range, 0.06-6.0 years). The incidence rate ratios for mortality and combined death and dialysis initiation were significantly lower in treated vs untreated patients (P<.001 for both in the fully adjusted models). Treatment with calcitriol was associated with a trend toward a lower incidence of dialysis. These results were consistent across different subgroups. Conclusions: Treatment with the activated vitamin D analogue calcitriol appears to be associated with significantly greater survival in patients with CKD not yet receiving dialysis. Randomized clinical trials are required to verify the causality of these associations and to examine whether similar associations are seen with different activated vitamin D analogues.

UR - http://www.scopus.com/inward/record.url?scp=40449107836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449107836&partnerID=8YFLogxK

U2 - 10.1001/archinternmed.2007.110

DO - 10.1001/archinternmed.2007.110

M3 - Article

VL - 168

SP - 397

EP - 403

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 4

ER -